Optimizing voriconazole susceptibility testing of Candida: Effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility

Journal of Clinical Microbiology

Volumn 37, Issue 9, 1999, Pages 2755-2759

  Lozano Chiu, M ^a,d   Arikan, S ^a,e   Paetznick, V L ^a   Anaissie, E J ^b   Rex, J H ^a,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c 1728 JFB ^*  (United States)

^d GLAXOSMITHKLINE   (Spain)

^e HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA GLABRATA; CANDIDA KRUSEI; CULTURE MEDIUM; DRUG SENSITIVITY; FUNGUS CULTURE; FUNGUS GROWTH; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032779922     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.9.2755-2759.1999     Document Type: Article

References (36)

1. Anaissie, E., V. Paetznick, and G. P. Bodey. 1991. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob. Agents Chemother. 35:1641-1646.
2. Anaissie, E. J., V. L. Paetznick, L. G. Ensign, A. Espinel-Ingroff, J. N. Galgiani, C. A. Hitchcock, M. LaRocco, T. Patterson, M. A. Pfaller, J. H. Rex, and M. G. Rinaldi. 1996. Microdilution antifungal susceptibility testing of Candida and Cryptococcus neoformans with and without agitation: an eight-center collaborative study. Antimicrob. Agents Chemother. 40:2387-2391.
3. Barry, A. L., and S. D. Brown. 1996. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40:1948-1949.
4. Dronda, F., M. Alonso-Sanz, F. Laguna, F. Chaves, J. V. Martinez-Suarez, J. L. Rodriguez-Tudela, A. Gonzalez-Lopez, and E. Valencia. 1996. Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 15:446-452.
5. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
6. Espinel-Ingroff, A., C. W. Kish, T. M. Kerkering, R. A. Fromtling, K. Bartizal, J. N. Galgiani, K. Villareal, M. A. Pfaller, T. Gerarden, M. G. Rinaldi, and A. Fothergill. 1992. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J. Clin. Microbiol. 30:3138-3145.
7. Espinel-Ingroff, A., L. Steele-Moore, and J. N. Galgiani. 1994. Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories. Diagn. Microbiol. Infect. Dis. 20:81-86.
8. Fratti, R. A., P. H. Belanger, A. S. Ibrahim, H. Sanati, and M. A. Ghannoum. 1996. The new triazole, voriconazole (UK-109,496) inhibits the growth of Candida krusei and its interactions with endothelial cells, abstr. C66, p. 46. In Abstracts of the 36th Interscience Conference on Antimicrobials Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Fromtling, R. A., J. N. Galgiani, M. A. Pfaller, A. Espinel-Ingroff, K. F. Bartizal, M. S. Bartlett, B. A. Body, C. Frey, G. Hall, G. D. Roberts, F. B. Nolte, F. C. Odds, M. G. Rinaldi, A. M. Sugar, and K. Villareal. 1993. Multicenter evaluation of a macrobroth antifungal susceptibility test for yeasts. Antimicrob. Agents Chemother. 37:39-45.
10. Gadea, I., M. Cuenca, M. I. Gegundez, J. Zapardiel, M. L. Valero, and F. Soriano. 1997. Effect of pH and buffer system on the in-vitro activity of five antifungals against yeasts. J. Antimicrob. Chemother. 39:453-459.
11. George, D., P. Miniter, and V. T. Andriole. 1996. Efficacy of UK-109,496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 40:86-91.
12. Ghannoum, M. A., A. S. Ibrahim, Y. Fu, M. C. Shafiq, J. E. Edwards, and R. S. Criddle. 1992. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J. Clin. Microbiol. 30:2881-2886.
13. Girmenia, C., G. Luzi, M. Monaco, and P. Martino. 1998. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J. Clin. Microbiol. 36:1436-1438.
14. Kauffman, C. A., and L. T. Zarins. 1998. In vitro activity of voriconazole against Candida species. Diagn. Microbiol. Infect. Dis. 31:297-300.
15. Lozano-Chiu, M., P. W. Nelson, M. Lancaster, M. A. Pfaller, and J. H. Rex. 1997. Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B. J. Clin. Microbiol. 35:270-272.
16. Lozano-Chiu, M., V. L. Paetznick, M. A. Ghannoum, and J. H. Rex. 1998. Detection of resistance to amphotericin B among clinical isolates of Cryptococcus neoformans: performance of three different media. J. Clin. Microbiol. 36:2817-2822.
17. Lozano-Chiu, M., P. W. Nelson, V. Paetznick, and J. H. Rex. 1997. Activity of voriconazole (VORI) vs. Candida: effects of incubation time, Candida species, and fluconazole (FLU) susceptibility, abstr. E-87, p. 129. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Martin, M. V., J. Yates, and C. A. Hitchcock. 1997. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob. Agents Chemother. 41:13-16.
19. McGinnis, M. R., L. Pasarell, D. A. Sutton, A. W. Fothergill, C. R. Cooper, and M. G. Rinaldi. 1997. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. 41:1832-1834.
20. Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
21. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. Nguyen, M. H., C. J. Clancy, V. L. Yu, Y. C. Yu, A. J. Morris, D. R. Snydman, D. A. Sutton, and M. G. Rinaldi. 1998. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis. 177:425-430.
23. Nguyen, M. H., and C. Y. Yu. 1998. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob. Agents Chemother. 42:471-472.
24. Nguyen, M. H., and C. Y. Yu. 1998. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compares with that of itraconazole and ketoconazole. J. Antimicrob. Chemother. 42:253-256.
25. Odds, F. C., L. Vranckx, and F. Woestenborghs. 1995. Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob. Agents Chemother. 39:2051-2060.
26. Pfaller, M. A., S. A. Messer, and S. Coffmann. 1995. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D070. J. Clin. Microbiol. 33:1094-1097.
27. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, G. V. Doern, M. E. Brandt, and R. A. Hajjeh. 1998. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob. Agents Chemother. 42:3242-3244.
28. Quereda, C., A. M. Polanco, C. Giner, A. Sanchez-Sousa, E. Pereira, E. Navas, J. Fortun, A. Guerrero, and F. Baquero. 1996. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 15:30-37.
29. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
30. Rex, J. H., C. R. Cooper, Jr., W. G. Merz, J. N. Galgiani, and E. J. Anaissie. 1995. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob. Agents Chemother. 39:906-909.
31. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
32. Rex, J. H., M. A. Pfaller, M. G. Rinaldi, A. Polak, and J. N. Galgiani. 1993. Antifungal susceptibility testing. Clin. Microbiol. Rev. 6:367-381.
33. Rodriguez-Tudela, J. L., and J. V. Martinez-Suarez. 1994. Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrob. Agents Chemother. 38:45-48.
34. Rodriguez-Tudela, J. L., J. V. Martinez-Suarez, F. Dronda, F. Chaves, and E. Valencia. 1995. Correlation of in vitro susceptibility test results with in vivo response: a study of azole therapy in AIDS patients. J. Antimicrob. Chemother. 35:793-804.
35. Ruhnke, M., A. Schmidt-Weshausen, and M. Trautmann. 1997. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:575-577.
36. Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39:2520-2522.